VolitionRx shares surge 22.22% intraday after announcing Nu.Q Cancer assay reimbursement submission in France with HCL support.

Volitionrx surged 22.22% intraday after announcing the preparation of its reimbursement submission for Nu.Q® Cancer assays in France, supported by the country’s second-largest hospital system, Hospices Civils de Lyon (HCL). The submission under the "Innovative Procedures Outside the Nomenclature" (RIHN) framework marks a critical step toward clinical adoption, with HCL emphasizing the test’s potential to enhance lung cancer management. The company highlighted Nu.Q®’s ability to improve patient stratification and treatment decisions, positioning it for routine use by late 2026 if approved. This regulatory progress aligns with Volitionrx’s strategy to commercialize its epigenetics-based diagnostics, offering a clear path to revenue growth through expanded market access in France and potential international licensing opportunities.